Drugs / TC-002
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05165290 | Nov 2021 → Sep 2022 | ocular hypertension | TearClear Corp | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TC-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05165290 ↗ |
| Known as | Latanoprost | “TC-002, TearClear latanoprost ophthalmic solution, 0.005%” NCT05165290 ↗ |
| Route | Topical | “delivered drop to the eye is preservative-free.” NCT05165290 ↗ |